Question · asked by 1 review

IVIg vs acetylsalicylic acid (ASA): Incidence of any adverse effects after treatment initiation (

It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of any adverse effects after treatment initiation (from 30… compared with acetylsalicylic acid (ASA) (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Primary treatment with intravenous immunoglobulin (IVIG) vs acetylsalicylic acid (ASA)
Incidence of any adverse effects after treatment initiation (from 30 days to 30 months) · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of any adverse effects after treatment initiation (from 30… compared with acetylsalicylic acid (ASA) (very low certainty).
Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane Headline outcomes only
OR 0.57 [0.17, 1.89]10 studies · 1376 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Intravenous immunoglobulin for the treatment of Kawasaki disease
2023 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.